Nuvectis Pharma Q1 net loss widens on higher expenses

Nuvectis Pharma

05/05/2026 12:39

Overview

US biopharma firm's Q1 net loss widened yr/yr on higher R&D and admin expenses

Cash and cash equivalents fell to $25.1 mln from $31.6 mln at year-end

Outlook

Company remains focused on achieving key clinical development milestones in 2026 and beyond

Result Drivers

R&D SPENDING - Higher research and development expenses driven by increased manufacturing, employee compensation, and clinical trial costs

ADMIN COSTS - General and administrative expenses rose due to higher professional and consulting services and employee compensation

Company press release: ID:nGNX5yQ8xV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.26
Q1 Net Income
-$6.05 mln
Q1 Operating Income
-$6.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Nuvectis Pharma Inc is $19.00, about 113.7% above its May 4 closing price of $8.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)